Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial
MS Rendell, J Rajfer, PA Wicker, MD Smith… - Jama, 1999 - jamanetwork.com
ContextErectile dysfunction is common in men with diabetes.ObjectiveTo assess the efficacy
and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with …
and safety of oral sildenafil citrate in the treatment of erectile dysfunction in men with …
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia
J Rosenstock, MS Rendell, JL Gross… - Diabetes, Obesity …, 2009 - Wiley Online Library
Aims: To assess the efficacy and safety of alogliptin added to insulin in patients with type 2
diabetes inadequately controlled with insulin alone or combined with metformin. Methods: In …
diabetes inadequately controlled with insulin alone or combined with metformin. Methods: In …
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo …
MS Kipnes, A Krosnick, MS Rendell, JW Egan… - The American journal of …, 2001 - Elsevier
PURPOSE: To evaluate the efficacy and tolerability of pioglitazone in combination with a
sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-…
sulfonylurea in the treatment of type 2 diabetes mellitus. SUBJECTS AND METHODS: This 16-…
[HTML][HTML] Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
…, A Pinckney, LA DiMeglio, MS Rendell… - The Journal of …, 2016 - Am Soc Clin Investig
BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by
autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would …
autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would …
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 …
MR Rigby, LA DiMeglio, MS Rendell… - The lancet Diabetes & …, 2013 - thelancet.com
Background Type 1 diabetes results from autoimmune targeting of the pancreatic β cells,
likely mediated by effector memory T (Tem) cells. CD2, a T cell surface protein highly …
likely mediated by effector memory T (Tem) cells. CD2, a T cell surface protein highly …
Manifestations of cutaneous diabetic microangiopathy
…, SK Srinivasan, CJ Huerter, MS Rendell - American journal of …, 2005 - Springer
The etiologies of a variety of skin conditions associated with diabetes have not been fully
explained. One possible etiological factor is diabetic microangiopathy, which is known to affect …
explained. One possible etiological factor is diabetic microangiopathy, which is known to affect …
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study
…, RL Dalman, S Panian, MS Rendell… - Vascular and …, 2002 - journals.sagepub.com
A multicenter, double-blind, randomized, placebo-controlled, parallel study was conducted
to compare the efficacy and safety of cilostazol 100 mg and 50 mg, both administered twice …
to compare the efficacy and safety of cilostazol 100 mg and 50 mg, both administered twice …
A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes
…, D Einhorn, CP Lucas, MS Rendell - Diabetes …, 1998 - search.proquest.com
… LUCAS, MD MARC S. RENnFi t, MD … Table S—Number of patients (96) with adverse
events possibly or probably related to study drug … Lins L, Brasseur R, Malaisse Wj: Conformational …
events possibly or probably related to study drug … Lins L, Brasseur R, Malaisse Wj: Conformational …
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
SH Tella, MS Rendell - Therapeutic advances in …, 2015 - journals.sagepub.com
Glucagon-like polypeptide (GLP-1) receptor agonist treatment has multiple effects on
glucose metabolism, supports the β cell, and promotes weight loss. There are now five GLP-1 …
glucose metabolism, supports the β cell, and promotes weight loss. There are now five GLP-1 …
DPP-4 inhibitors: focus on safety
SH Tella, MS Rendell - Expert opinion on drug safety, 2015 - Taylor & Francis
Introduction: Dipeptidyl peptidase inhibitors (DPP-4-i) are highly selective inhibitors of the
enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent effects …
enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent effects …